|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
JP5238936B2
(ja)
|
2005-03-25 |
2013-07-17 |
ジーアイティーアール，インク． |
Ｇｉｔｒ結合分子およびその使用
|
|
DK1879573T3
(da)
|
2005-05-10 |
2013-02-25 |
Incyte Corp |
Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
WO2007041511A2
(en)
|
2005-09-30 |
2007-04-12 |
New York University |
Hematopoietic progenitor kinase 1 for modulation of an immune response
|
|
ES2540561T3
(es)
|
2005-12-20 |
2015-07-10 |
Incyte Corporation |
N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
|
|
TW200808739A
(en)
*
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
|
WO2007125405A2
(en)
|
2006-05-01 |
2007-11-08 |
Pfizer Products Inc. |
Substituted 2-amino-fused heterocyclic compounds
|
|
CA2663057C
(en)
|
2006-09-19 |
2015-12-08 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
|
CL2007002650A1
(es)
|
2006-09-19 |
2008-02-08 |
Incyte Corp |
Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
US9603848B2
(en)
|
2007-06-08 |
2017-03-28 |
Senomyx, Inc. |
Modulation of chemosensory receptors and ligands associated therewith
|
|
PT2175884T
(pt)
|
2007-07-12 |
2016-09-21 |
Gitr Inc |
Terapias de combinação empregando moléculas de ligação a gitr
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
WO2009073620A2
(en)
|
2007-11-30 |
2009-06-11 |
Newlink Genetics |
Ido inhibitors
|
|
GB0803018D0
(en)
|
2008-02-19 |
2008-03-26 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
JP5789252B2
(ja)
|
2009-05-07 |
2015-10-07 |
インテリカイン， エルエルシー |
複素環式化合物およびその使用
|
|
WO2012020742A1
(ja)
|
2010-08-10 |
2012-02-16 |
塩野義製薬株式会社 |
新規複素環誘導体およびそれらを含有する医薬組成物
|
|
NZ729044A
(en)
|
2010-09-09 |
2020-07-31 |
Pfizer |
4-1bb binding molecules
|
|
NO2694640T3
(cg-RX-API-DMAC10.html)
|
2011-04-15 |
2018-03-17 |
|
|
|
CA2833636A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
BR112014012819B1
(pt)
|
2011-11-28 |
2022-08-16 |
Merck Patent Gmbh |
Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
|
|
GB201120993D0
(en)
|
2011-12-06 |
2012-01-18 |
Imp Innovations Ltd |
Novel compounds and their use in therapy
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
CA2881279C
(en)
*
|
2012-08-07 |
2020-07-07 |
Merck Patent Gmbh |
Pyridopyrimidine derivatives as protein kinase inhibitors
|
|
GB201216017D0
(en)
*
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
|
TW201542538A
(zh)
|
2013-07-16 |
2015-11-16 |
奇尼塔公司 |
抗病毒化合物、醫藥組合物及其使用方法
|
|
JP6899323B2
(ja)
|
2014-10-14 |
2021-07-07 |
ラ ホーヤ インスティテュート オブ アレルギー アンド イミュノロジー |
低分子量タンパク質チロシンホスファターゼの阻害剤、及びその使用
|
|
EP3270694A4
(en)
|
2015-02-17 |
2018-09-05 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
US20180072718A1
(en)
*
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyridine compounds and uses thereof
|
|
US11180482B2
(en)
*
|
2016-11-30 |
2021-11-23 |
Ariad Pharmaceuticals, Inc. |
Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
|
|
CN110678466B
(zh)
*
|
2017-03-30 |
2023-01-31 |
豪夫迈·罗氏有限公司 |
作为hpk1抑制剂的二氮杂萘类
|
|
EP3652174A4
(en)
|
2017-07-13 |
2021-06-30 |
Syros Pharmaceuticals, Inc. |
TAM KINASE INHIBITORS
|
|
JP7386841B2
(ja)
*
|
2018-07-24 |
2023-11-27 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
イソキノリン化合物及びその使用
|
|
JP7386842B2
(ja)
*
|
2018-07-24 |
2023-11-27 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
ナフチリジン化合物およびその使用
|
|
WO2021000935A1
(en)
|
2019-07-04 |
2021-01-07 |
Qilu Regor Therapeutics Inc. |
Hpk1 inhibitors and uses thereof
|
|
PH12022551574A1
(en)
|
2019-12-23 |
2024-02-26 |
Blueprint Medicines Corp |
Egfr inhibitors
|
|
EP4090663A1
(en)
|
2020-01-15 |
2022-11-23 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
|
JP2024510176A
(ja)
|
2021-03-08 |
2024-03-06 |
ブループリント メディシンズ コーポレイション |
Ｍａｐ４ｋ１阻害剤
|
|
MX2024000751A
(es)
|
2021-07-14 |
2024-03-25 |
Blueprint Medicines Corp |
Compuestos heterociclicos como inhibidores de map4k1.
|